Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-AM-01
- Development stage
- Unknown
- Lead developer
- Curatis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
C-AM-01 is a repurposed formulation of picotamide, a small molecule dual thromboxane A2 (TXA2) synthase inhibitor and thromboxane A2 receptor (TP) antagonist. Developed by Curatis Group and its spin-off CapiThera, it is currently in Phase 2 clinical development for the prevention of severe migraine with aura (MwA). By targeting both the production and the receptor-mediated actions of thromboxane A2, C-AM-01 aims to address the vasoactive and pro-thrombotic mechanisms associated with the cortical spreading depression and vascular changes characteristic of migraine with aura. The drug addresses a significant unmet medical need in the severe segment of patients with aura.
- Other names
- picotamide
02
Targets
TBXAS1 (Thromboxane A2 synthase)TYMP (Thymidine phosphorylase)
Beyond the preview
Go deeper on C-AM-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-AM-01.